Nothing Special   »   [go: up one dir, main page]

CL2016000232A1 - Estabilización de polipéptidos que contienen fragmentos cristalizables - Google Patents

Estabilización de polipéptidos que contienen fragmentos cristalizables

Info

Publication number
CL2016000232A1
CL2016000232A1 CL2016000232A CL2016000232A CL2016000232A1 CL 2016000232 A1 CL2016000232 A1 CL 2016000232A1 CL 2016000232 A CL2016000232 A CL 2016000232A CL 2016000232 A CL2016000232 A CL 2016000232A CL 2016000232 A1 CL2016000232 A1 CL 2016000232A1
Authority
CL
Chile
Prior art keywords
stabilization
polypeptides containing
containing crystallizable
crystallizable fragments
replacement
Prior art date
Application number
CL2016000232A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Frederick W Jacobsen
Jennifer Lavallee
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2016000232A1 publication Critical patent/CL2016000232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

POLIPÉPTIDO QUE COMPRENDE UNA REGIÓN Fc DE ANTICUERPO CON UNA DELECIÓN O SUSTITUCIÓN DE UNA O MÁS CISTEÍNAS EN LA REGIÓN BISAGRA Y UNA SUSTITUCIÓN CON UN RESIDUO QUE CONTIENE SULFIHIDRILO EN UNO A MÁS AMINOÁCIDOS EN LA INTERFASE CH3; ÁCIDO NUCLEICO; VECTOR; CÉLULA HOSPEDERA; MÉTODO DE ELABORACIÓN; Y COMPOSICIÓN FARMACÉUTICA.
CL2016000232A 2013-07-31 2016-01-28 Estabilización de polipéptidos que contienen fragmentos cristalizables CL2016000232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
CL2016000232A1 true CL2016000232A1 (es) 2016-09-02

Family

ID=52432568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000232A CL2016000232A1 (es) 2013-07-31 2016-01-28 Estabilización de polipéptidos que contienen fragmentos cristalizables

Country Status (15)

Country Link
US (2) US20160193295A1 (es)
EP (1) EP3027647A4 (es)
JP (2) JP2016526909A (es)
KR (2) KR20230141929A (es)
CN (1) CN105658664A (es)
AU (3) AU2014296215A1 (es)
BR (1) BR112016002219A2 (es)
CA (1) CA2919076C (es)
CL (1) CL2016000232A1 (es)
EA (1) EA035319B1 (es)
HK (1) HK1224203A1 (es)
IL (1) IL243690B (es)
MX (2) MX2016001165A (es)
SG (1) SG11201600734YA (es)
WO (1) WO2015017548A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MD20170020A2 (ro) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
UA121973C2 (uk) * 2014-10-31 2020-08-25 Нджм Біофармасьютікалз, Інк. Комплекс, що має активність фактора диференціації росту 15 (gdf15), та способи лікування ним ожиріння та гіперглікемії у суб'єкта
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
PE20180778A1 (es) 2015-08-07 2018-05-07 Alexo Therapeutics Inc Construcciones con un dominio sirp-alfa o sus variantes
AU2017269115B2 (en) 2016-05-26 2024-06-20 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2018005226A2 (en) * 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CN117024560A (zh) * 2016-12-22 2023-11-10 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018144784A1 (en) * 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
CA3069119A1 (en) * 2017-07-07 2019-01-10 Hanmi Pharm. Co., Ltd. Novel therapeutic enzyme fusion protein and use thereof
US20200362034A1 (en) * 2017-08-15 2020-11-19 Kindred Biosciences, Inc. IgG Fc Variants for Veterinary Use
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
JP7403455B2 (ja) * 2017-12-22 2023-12-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
EP3829633A1 (en) 2018-08-03 2021-06-09 Amgen Research (Munich) GmbH Antibody constructs for cldn18.2 and cd3
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
WO2021108628A1 (en) 2019-11-25 2021-06-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CA3159979A1 (en) * 2019-12-11 2021-06-17 Yeonchul Kim Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
MX2022014636A (es) 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR20240007913A (ko) 2021-05-13 2024-01-17 알렉소 온콜로지 인크. 암 치료를 위한 병용 요법
WO2023025123A1 (zh) * 2021-08-24 2023-03-02 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) * 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR20080090406A (ko) * 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
WO2011063348A1 (en) * 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
HUE043355T2 (hu) 2010-12-06 2019-08-28 Seattle Genetics Inc LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében

Also Published As

Publication number Publication date
CA2919076C (en) 2024-01-30
WO2015017548A3 (en) 2015-11-05
HK1224203A1 (zh) 2017-08-18
WO2015017548A2 (en) 2015-02-05
MX2022008013A (es) 2022-07-27
EP3027647A4 (en) 2017-01-04
EP3027647A2 (en) 2016-06-08
KR20230141929A (ko) 2023-10-10
SG11201600734YA (en) 2016-02-26
JP2021019598A (ja) 2021-02-18
JP2016526909A (ja) 2016-09-08
AU2020200329A1 (en) 2020-02-06
CA2919076A1 (en) 2015-02-05
JP7344858B2 (ja) 2023-09-14
AU2022201204A1 (en) 2022-03-17
US20190192628A1 (en) 2019-06-27
BR112016002219A2 (pt) 2017-09-12
KR20160034404A (ko) 2016-03-29
IL243690A0 (en) 2016-04-21
IL243690B (en) 2022-09-01
US20160193295A1 (en) 2016-07-07
EA035319B1 (ru) 2020-05-27
MX2016001165A (es) 2016-06-29
EA201690299A1 (ru) 2016-11-30
CN105658664A (zh) 2016-06-08
AU2014296215A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
BR112015024587A2 (pt) variante de região fc
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
EP3044323A4 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
EA201590061A1 (ru) Фармацевтическая композиция
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
PE20151757A1 (es) Anticuerpos anti-cd52
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
BR112018005464A2 (pt) expressão de proteínas contendo fc
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
AR099080A1 (es) Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas
EA201992746A2 (ru) Рекомбинантные гликопротеиды и их применения